Abbott D et al. Overall Survival and its interplay with allogeneic stem cell transplant and age in newly diagnosed AML patients treated with ven/aza. ASH 2022;Abstract 2751.
Brunner AM et al. Efficacy and safety of sabatolimab (MBG453) in combination with hypomethylating agents (HMAs) in patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS): Updated results from a phase 1b study. ASH 2020;Abstract 657.
Byrd JC et al. Acalabrutinib in treatment-naïve chronic lymphocytic leukemia: Mature results from phase 2 study demonstrating durable remissions and long-term tolerability. EHA 2022;Abstract P525.
Carvajal LA et al. SYK inhibitors, entospletinib and lanraplenib, show potent anti-leukemic activity in combination with targeted agents. ASH 2022;Abstract 2639.
Chua CC et al. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv 2022;6(13):3879-83. Abstract
Cherry EM et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv 2021;5(24):5565-73. Abstract
Day MA et al. CDK9 inhibition via KB-0742 is a potential strategy to treat transcriptionally addicted cancers. AACR 2022;Abstract 2564.
Day MAL et al. Preclinical activity of selective SYK inhibitors, entospletinib and lanraplenib, alone or in combination with targeted agents in ex vivo AML models with diverse mutational backgrounds. ASH 2021;Abstract 3356.
Döhner H et al. ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine. ASH 2022;Abstract 602.
Garcia-Manero G et al. ASTX727-03: Phase 1 study evaluating oral decitabine/cedazuridine (ASTX727) low-dose (LD) in lower-risk myelodysplastic syndromes (LR-MDS) patients. ASH 2022;Abstract 461.
Geissler K et al. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized crossover phase 3 study of an oral hypomethylating agent DEC-C compared to IV decitabine in AML patients. EHA 2022;Abstract P573.
Gutman JA et al. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed patients with acute myeloid leukemia: Phase 2 Hiddav study. ASH 2022;Abstract 1421.
Hayden A et al. Clinical and molecular features of highly durable response to azacitidine + venetoclax in acute myeloid leukemia. ASH 2022;Abstract 4129.
Kambhampati S et al. Initial results from SELECT-AML-1, a phase 2 study of tamibarotene in combination with venetoclax and azacitidine in RARA-positive newly diagnosed AML patients ineligible for standard induction chemotherapy. ASH 2022;Abstract 1444.
Khanna V et al. Outcomes with molecularly targeted agents as salvage therapy following frontline HMA/venetoclax in adults with acute myeloid leukemia: A multi-center retrospective analysis. ASH 2022;Abstract 1429.
Kühn MWM et al. Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia. Cancer Discov 6(10):1166-81. Abstract
Madarang E et al. Toxicity and outcomes in octo- and nonagenarians with AML treated with venetoclax and hypomethylating agent therapy. ASH 2022;Abstract 1434.
McMahon CM et al. Response to intensive induction chemotherapy after failure of frontline azacitidine + venetoclax in acute myeloid leukemia. ASH 2022;Abstract 2753.
Minhujuddin M et al. Molecular MRD by digital PCR is prognostic of outcomes in AML patients on intensive and non-intensive treatment regimens. ASH 2022;Abstract 2791.
Pollyea DA et al. Impact of venetoclax and azacytidine in treatment-niave patients with acute myeloid leukemia in IDH1/2 mutations. Clin Cancer Res 2022;28(13):2753-61. Abstract
Pollyea DA et al. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine. Clin Cancer Res 2022;[Online ahead of print]. Abstract
Scott BL et al. Treatment patterns and outcomes of patients with primary or secondary acute myeloid leukemia by type of site (academic or community/government): A CONNECT® Myeloid Registry study. ASH 2022;Abstract 4023.
Ucklemann HJ et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Cancer Discov 2020;367(6477):586-90. Abstract
Walker AR et al. Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: Response and predictive significance of HOXA9 and MEIS1 expression. Clin Cancer Res 2020;26(22):5852-9. Abstract
Walker AR et al. Results of a phase 1b/2 study of entospletinib (GS-9973) monotherapy and in combination with induction chemotherapy in newly diagnosed patients with acute myeloid leukemia. EHA 2018;Abstract S118.
Wolach O et al. Comparison of patients with newly diagnosed (ND) acute myeloid leukemia (AML) treated with venetoclax and hypomethylating agents vs other therapies by TP53 and IDH1/2 mutation: Results from the AML real world evidence (ARC) initiative. ASH 2022;Abstract 4954.
Zeidan AM et al. Real-world efficacy outcomes of venetoclax plus azacitidine vs intensive chemotherapy for induction therapy in adult patients with acute myeloid leukemia. EHA 2022;Abstract P570.